On January 20, Sonoma Pharmaceuticals Inc. (SNOA) announced its partner network expansion for oral and dental products in the U.S. and China. Following the announcement,
Sonoma Pharmaceuticals, Inc. (SNOA) stock prices were down 18.88% some time after market trading commenced on July 15th, 2021, bringing the price per share down
Sonoma Pharmaceuticals Inc. (SNOA) stock surged by 8.47% at the last trading close whereas the SNOA rises by 26.78% in the pre-market trading after it
Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under
Sonoma Pharmaceuticals Inc. (SNOA) stock plunged -7.53% to $8.1 in the pre-market trading after reporting partnership with Crown Laboratories to launch Microcyn® technology-based anti-itch over-the-counter
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) shares hiked 32.30% to reach $8.11 in the pre-market session after the announcement that they have reached a license and
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a multinational healthcare giant, has released financial results for its second fiscal quarter and six months ended September 30, 2020,
The equity markets have regained upside momentum this afternoon. This follows the Fed’s decision to keep supporting the markets. A statement from the FOMC said
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.